Boehringer calls off €627M deal with GSK spin­out, pass­ing on schiz­o­phre­nia drug op­tion

Boehringer In­gel­heim has walked away from a schiz­o­phre­nia pro­gram it once called an “un­prece­dent­ed ther­a­peu­tic con­cept,” tak­ing €627.5 mil­lion off the ta­ble for its biotech part­ner.

Steve­nage, UK-based Au­ti­fony not­ed that over the past three years, it’s col­lab­o­rat­ed with Boehringer to demon­strate tar­get en­gage­ment, bio­mark­er da­ta and safe­ty for its lead Kv3 mod­u­la­tor, AUT00206, as well as mov­ing a sec­ond mol­e­cule in­to Phase I.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER